Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Diagnosis and Management of Latent Tuberculosis Infection: Updates

Author(s): Satish Swain, Arvind Kumar*, Vishal Kumar Vishwakarma, Adarsh Aayilliath K, Ankit Mittal and Naveet Wig

Volume 24, Issue 4, 2024

Published on: 28 November, 2023

Article ID: e281123223933 Pages: 8

DOI: 10.2174/0118715265275319231124053615

Price: $65

Abstract

India has the largest problem of tuberculosis (TB) infection globally (estimated at about 35-40 crores cases), and around 18-36 lakh develop active tuberculosis annually. Latent TB is defined as a state of persistent immune response to stimulation by Mycobacterium tuberculosis antigens with no evidence of clinically manifested active TB. The progression of a latent infection to active tuberculosis increases several-fold in children < 5 years of age and in people with some or the other form of an immunocompromising condition. Therefore, to cater to this gigantic problem of tuberculosis, it is necessary to have awareness about latent tuberculosis infection (LTBI) amongst clinicians and to prioritise its diagnosis and treatment in high-risk groups. India plans to end TB well before the deadline set by the World Health organisation (WHO). However, this can only be achieved with effective strategies targeting LTBI. Multiple treatment regimens have been approved for LTBI treatment, and all have comparable efficacy. The selection of one regimen over the other depends on various factors, such as availability, risk of adverse events, age, and drug interactions. Recently, the WHO, as well as the Revised National TB Control Programme (RNTCP), have updated their guidelines on TB preventive treatment in 2020 and 2021, respectively. This review has been especially prepared to acknowledge the differences in approach to LTBI in developed and developing countries.

Graphical Abstract

[1]
Behr MA, Kaufmann E, Duffin J, Edelstein PH, Ramakrishnan L. Latent tuberculosis: Two centuries of confusion. Am J Respir Crit Care Med 2021; 204(2): 142-8.
[http://dx.doi.org/10.1164/rccm.202011-4239PP] [PMID: 33761302]
[2]
Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis 1999; 3(10): 847-50.
[PMID: 10524579]
[3]
Horsburgh CR Jr, Rubin EJ. Clinical practice. Latent tuberculosis infection in the United States. N Engl J Med 2011; 364(15): 1441-8.
[http://dx.doi.org/10.1056/NEJMcp1005750] [PMID: 21488766]
[4]
Bibbins-Domingo K, Grossman DC, Curry SJ, et al. Screening for latent tuberculosis infection in adults. JAMA 2016; 316(9): 962-9.
[http://dx.doi.org/10.1001/jama.2016.11046] [PMID: 27599331]
[5]
Sosa LE, Njie GJ, Lobato MN, et al. Tuberculosis screening, testing, and treatment of U.S. Health Care Personnel: Recommendations from the National Tuberculosis Controllers Association and CDC, 2019. MMWR Morb Mortal Wkly Rep 2019; 68(19): 439-43.
[http://dx.doi.org/10.15585/mmwr.mm6819a3] [PMID: 31099768]
[6]
Marais BJ, Gie RP, Schaaf HS, et al. The natural history of childhood intra-thoracic tuberculosis: A critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis 2004; 8(4): 392-402.
[PMID: 15141729]
[7]
Comstock GW, Edwards LB, Livesay VT. Tuberculosis morbidity in the U.S. Navy: Its distribution and decline. Am Rev Respir Dis 1974; 110(5): 572-80.
[PMID: 4429253]
[8]
WHO. WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment. World Health Organization Geneva 2020.
[9]
Central TB. Division Guidelines for Programmatic Management of Tuberculosis Preventive Treatment in India. 2015. Available From https://www.tbcindia.gov.in/WriteReadData/l892s/Guidelines%20for%20Programmatic%20Management%20of%20Tuberculosis%20Preventive%20Treatment%20in%20India.pdf
[10]
Pathakumari B, Devasundaram S, Raja A. Altered expression of antigen-specific memory and regulatory T-cell subsets differentiate latent and active tuberculosis. Immunology 2018; 153(3): 325-36.
[http://dx.doi.org/10.1111/imm.12833] [PMID: 28881482]
[11]
Barcellini L, Borroni E, Brown J, et al. First evaluation of QuantiFERON-TB Gold Plus performance in contact screening. Eur Respir J 2016; 48(5): 1411-9.
[http://dx.doi.org/10.1183/13993003.00510-2016] [PMID: 27390280]
[12]
Saha S, Kumar A, Saurabh K, et al. Current status of treatment of latent tuberculosis infection in India. Indian J Med Sci 2020; 71(2): 54-9.
[http://dx.doi.org/10.25259/IJMS_18_2019]
[13]
American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recomm Rep 2000; 49(RR-6): 1-51.
[PMID: 10881762]
[14]
Aggerbeck H, Ruhwald M, Hoff ST, et al. C-Tb skin test to diagnose Mycobacterium tuberculosis infection in children and HIV-infected adults: A phase 3 trial. PLoS One 2018; 13(9): e0204554.
[http://dx.doi.org/10.1371/journal.pone.0204554] [PMID: 30248152]
[15]
Ruhwald M, Aggerbeck H, Gallardo RV, et al. Safety and efficacy of the C-Tb skin test to diagnose Mycobacterium tuberculosis infection, compared with an interferon γ release assay and the tuberculin skin test: A phase 3, double-blind, randomised, controlled trial. Lancet Respir Med 2017; 5(4): 259-68.
[http://dx.doi.org/10.1016/S2213-2600(16)30436-2] [PMID: 28159608]
[16]
Park HD, Guinn KM, Harrell MI, et al. Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis. Mol Microbiol 2003; 48(3): 833-43.
[http://dx.doi.org/10.1046/j.1365-2958.2003.03474.x] [PMID: 12694625]
[17]
Hozumi H, Tsujimura K, Yamamura Y, et al. Immunogenicity of dormancy-related antigens in individuals infected with Mycobacterium tuberculosis in Japan. Int J Tuberc Lung Dis 2013; 17(6): 818-24.
[http://dx.doi.org/10.5588/ijtld.12.0695] [PMID: 23676169]
[18]
Goletti D, Butera O, Vanini V, et al. Response to Rv2628 latency antigen associates with cured tuberculosis and remote infection. Eur Respir J 2010; 36(1): 135-42.
[http://dx.doi.org/10.1183/09031936.00140009] [PMID: 19926735]
[19]
Meier NR, Jacobsen M, Ottenhoff THM, Ritz N. A Systematic Review on Novel Mycobacterium tuberculosis Antigens and Their Discriminatory Potential for the Diagnosis of Latent and Active Tuberculosis. Front Immunol 2018; 9: 2476.
[http://dx.doi.org/10.3389/fimmu.2018.02476] [PMID: 30473692]
[20]
Jacobs AJ, Mongkolsapaya J, Screaton GR, McShane H, Wilkinson RJ. Antibodies and tuberculosis. Tuberculosis (Edinb) 2016; 101: 102-13.
[http://dx.doi.org/10.1016/j.tube.2016.08.001] [PMID: 27865379]
[21]
de Araujo LS, da Silva NBM, Leung JAM, Mello FCQ, Saad MHF. IgG subclasses’ response to a set of mycobacterial antigens in different stages of Mycobacterium tuberculosis infection. Tuberculosis (Edinb) 2018; 108: 70-6.
[http://dx.doi.org/10.1016/j.tube.2017.10.010] [PMID: 29523330]
[22]
Fletcher HA, Snowden MA, Landry B, et al. T-cell activation is an immune correlate of risk in BCG vaccinated infants. Nat Commun 2016; 7(1): 11290.
[http://dx.doi.org/10.1038/ncomms11290] [PMID: 27068708]
[23]
Coppola M, Arroyo L, van Meijgaarden KE, et al. Differences in IgG responses against infection phase related Mycobacterium tuberculosis (Mtb) specific antigens in individuals exposed or not to Mtb correlate with control of TB infection and progression. Tuberculosis (Edinb) 2017; 106: 25-32.
[http://dx.doi.org/10.1016/j.tube.2017.06.001] [PMID: 28802401]
[24]
Ford N, Matteelli A, Shubber Z, et al. TB as a cause of hospitalization and in-hospital mortality among people living with HIV worldwide: A systematic review and meta-analysis. J Int AIDS Soc 2016; 19(1): 20714.
[http://dx.doi.org/10.7448/IAS.19.1.20714] [PMID: 26765347]
[25]
World Health Organization WHO consolidated guidelines on tuberculosis: Module 1: Prevention: Tuberculosis preventive treatment. 2020. Available From https://www.who.int/publications-detail-redirect/9789240001503
[26]
Mtei L, Matee M, Herfort O, et al. High rates of clinical and subclinical tuberculosis among HIV-infected ambulatory subjects in Tanzania. Clin Infect Dis 2005; 40(10): 1500-7.
[http://dx.doi.org/10.1086/429825] [PMID: 15844073]
[27]
World Health Organization Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: Recommendations for a public health approach. 2021. Available From https://www.who.int/publications-detail-redirect/9789240031593
[28]
Marks SM, Mase SR, Morris SB. Systematic review, meta-analysis, and cost-effectiveness of treatment of latent tuberculosis to reduce progression to multidrug-resistant tuberculosis. Clin Infect Dis 2017; 64(12): 1670-7.
[http://dx.doi.org/10.1093/cid/cix208] [PMID: 28329197]
[29]
Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Libr 2010; 2010(1): CD000171.
[http://dx.doi.org/10.1002/14651858.CD000171.pub3] [PMID: 20091503]
[30]
Sharma SK, Sharma A, Kadhiravan T, Tharyan P. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Cochrane Libr 2013; 2013(7): CD007545.
[http://dx.doi.org/10.1002/14651858.CD007545.pub2] [PMID: 23828580]
[31]
Campbell JR, Al-Jahdali H, Bah B, et al. Safety and efficacy of rifampin or isoniazid among people with Mycobacterium tuberculosis infection and living with human immunodeficiency virus or other health conditions: Post hoc analysis of 2 randomized trials. Clin Infect Dis 2021; 73(9): e3545-54.
[http://dx.doi.org/10.1093/cid/ciaa1169] [PMID: 32785709]
[32]
Campbell JR, Trajman A, Cook VJ, et al. Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: Post-hoc safety analysis of two randomised controlled trials. Lancet Infect Dis 2020; 20(3): 318-29.
[http://dx.doi.org/10.1016/S1473-3099(19)30575-4] [PMID: 31866327]
[33]
Zenner D, Beer N, Harris RJ, Lipman MC, Stagg HR, van der Werf MJ. Treatment of latent tuberculosis infection. Ann Intern Med 2017; 167(4): 248-55.
[http://dx.doi.org/10.7326/M17-0609] [PMID: 28761946]
[34]
Stagg HR, Zenner D, Harris RJ, Muñoz L, Lipman MC, Abubakar I. Treatment of latent tuberculosis infection: A network meta-analysis. Ann Intern Med 2014; 161(6): 419-28.
[http://dx.doi.org/10.7326/M14-1019] [PMID: 25111745]
[35]
Swindells S, Ramchandani R, Gupta A, et al. One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis. N Engl J Med 2019; 380(11): 1001-11.
[http://dx.doi.org/10.1056/NEJMoa1806808] [PMID: 30865794]
[36]
Saunders MJ, Evans CA. Ending tuberculosis through prevention. N Engl J Med 2019; 380(11): 1073-4.
[http://dx.doi.org/10.1056/NEJMe1901656] [PMID: 30865803]
[37]
Mirsaeidi M. Rifapentine and isoniazid for latent tuberculosis. N Engl J Med 2012; 366(15): 1447-8.
[http://dx.doi.org/10.1056/NEJMc1200489] [PMID: 22494128]
[38]
WHO Recommendation on 36 months isoniazid preventive therapy to adults and adolescents living with HIV in resource-constrained and high TB- and HIV-prevalence settings – 2015 update (WHO/HTM/TB/201515/WHO/HIV/201513). Geneva: World Health Organization 2015.
[39]
Kapoor S, Gupta A, Shah M. Cost-effectiveness of isoniazid preventive therapy for HIV-infected pregnant women in India. Int J Tuberc Lung Dis 2016; 20(1): 85-92.
[http://dx.doi.org/10.5588/ijtld.15.0391] [PMID: 26688533]
[40]
Kim H-Y, Hanrahan CF, Martinson N, Golub JE, Dowdy DW. Cost-effectiveness of universal isoniazid preventive therapy among HIV-infected pregnant women in South Africa. Int J Tuberc Lung Dis 2018; 22(12): 1435-42.
[http://dx.doi.org/10.5588/ijtld.18.0370] [PMID: 30606315]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy